Danaher earnings release, July 21, 2026

Danaher Corp (DHR) · Form 8-K, Item 2.02 · Filed · SEC filing

Innovation at the speed of life

Danaher Reports Second Quarter 2026 Results

WASHINGTON D.C., July 21, 2026 -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Key Second Quarter 2026 Results

• Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year.

• Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94.

• Revenues increased 5.5% year-over-year to $6.3 billion.

• Non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year.

• Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.3 billion.

• Strong Q2 earnings performance and earlier-than-anticipated completion of Masimo acquisition enabling increased full year 2026 adjusted diluted net earnings per common share guidance.

Rainer M. Blair, President and Chief Executive Officer, stated, “We delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth. Our Life Sciences businesses delivered their strongest quarter in several years and while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter.”

Mr. Blair continued, “Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate. Longer term, Danaher’s leading portfolio, capital deployment optionality and talented team — all powered by the Danaher Business System — position us to accelerate the impact of science and technology, help customers move from discovery to delivery faster, and create sustainable long-term shareholder value.”

Third Quarter and Full Year 2026 Outlook

Danaher Corporation (the “Company”) does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $0.5 billion for the third quarter and $1.9 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which is estimated to decrease sales by 1.0% in the third quarter and increase sales by 0.5% in the full year, assuming the currency exchange rates in effect as of June 26, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, future acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP.

For the third quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the 2.0% to 3.0% range year-over-year.

For full year 2026, the Company expects non-GAAP core revenue will increase in the 3.0% to 4.0% range year-over-year. The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 versus previous guidance of $8.35 to $8.55.

Conference Call and Webcast Information

Danaher will discuss its second quarter results and financial guidance for the third quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the “Investors” section of Danaher’s website, www.danaher.com, under the subheading “Events & Presentations.” A replay of the webcast will be available in the same section of Danaher’s website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.¹

The conference call can be accessed by dialing 833-419-0865, within the U.S. or +1 785-838-9333 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ226). A replay of the conference call will be available shortly after the conclusion of the call and until August 4, 2026. You can access the replay dial-in information on the “Investors” section of Danaher’s website under the subheading “Events & Presentations.”

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS... (truncated) earnings release also contains non-GAAP financial measures. Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the “Investors” section of Danaher’s website (www.danaher.com).

Financial statements

Income Statement

Three-Month Period Ended — (unaudited)

Three-Month Period Ended – June 26, 2026Three-Month Period Ended – June 27, 2025Six-Month Period Ended – June 26, 2026Six-Month Period Ended – June 27, 2025
Sales6,2655,93612,21611,677
Cost of sales-2,654-2,413-5,014-4,643
Gross profit3,6113,5237,2027,034
Operating costs:Selling, general and administrative expenses-2,072-2,360-3,932-4,218
Operating costs:Research and development expenses-412-403-799-782
Operating costs:Operating profit1,1277602,4712,034
Nonoperating income (expense):Other income (expense), net-3-42-76-121
Nonoperating income (expense):Interest expense-107-71-170-143
Nonoperating income (expense):Interest income6188814
Nonoperating income (expense):Earnings before income taxes1,0786552,3131,784
Nonoperating income (expense):Income taxes-208-100-414-275
Nonoperating income (expense):Net earnings8705551,8991,509
Net earnings per common share:Basic1.230.772.692.11
Net earnings per common share:Diluted1.230.772.682.1
Average common stock and common equivalent shares outstanding:Basic705.3716.5706.6716.4
Average common stock and common equivalent shares outstanding:Diluted707.6719.1709.4719.9

Cash Flow

Three-Month Period Ended — ($ in millions)

Three-Month Period Ended – June 26, 2026Three-Month Period Ended – June 27, 2025Six-Month Period Ended – June 26, 2026Six-Month Period Ended – June 27, 2025
Total Cash Flow:Net cash provided by operating activities (GAAP)1,5341,3382,8562,637
Total Cash Flow:Total cash used in investing activities (GAAP)-10,147-258-10,396-500
Total Cash Flow:Total cash provided by (used in) financing activities (GAAP)7,273-2477,319-1,502
Free Cash Flow:Net cash provided by operating activities (GAAP)1,5341,3382,8562,637
Free Cash Flow:Less: payments for additions to property, plant & equipment (capital expenditures) (GAAP)-269-248-506-493
Free Cash Flow:Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)410
Free Cash Flow:Free cash flow (non-GAAP)1,2651,0942,3502,154
Operating Cash Flow to Net Earnings Conversion Ratio:Net cash provided by operating activities (GAAP)1,5341,3382,8562,637
Operating Cash Flow to Net Earnings Conversion Ratio:Net earnings (GAAP)8705551,8991,509
Operating Cash Flow to Net Earnings Conversion Ratio:Operating cash flow to net earnings conversion ratio (GAAP)1.762.411.51.75
Free Cash Flow to Net Earnings Conversion Ratio:Free cash flow from above (non-GAAP)1,2651,0942,3502,154
Free Cash Flow to Net Earnings Conversion Ratio:Net earnings (GAAP)8705551,8991,509
Free Cash Flow to Net Earnings Conversion Ratio:Free cash flow to net earnings conversion ratio (non-GAAP)1.451.971.241.43
Full release

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

Statements in this release that are not strictly historical, including the statements regarding the Company’s anticipated financial results for the third quarter and full year 2026, the Company’s expectations regarding growth and market recovery, the Company’s positioning to create long-term shareholder value, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo Corporation), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to² address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2026. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.... (truncated) may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.

CONTACT

• Investor: Rachel Vatnsdal, Vice President, Investor Relations, investor.relations@danaher.com

• Media: media@danaher.com

Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037,

Telephone: (202) 828-0850, Fax: (202) 828-0860³

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Danaher earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.